Tirzepatide injection significantly reduces blood sugar and body weight! It has not been studied in patients with a history of pancreatitis and is not intended for patients with type 1 diabetes (T1D).
Details:
Tirzepatide injection significantly reduces blood sugar and body weight! It has not been studied in patients with a history of pancreatitis and is not intended for patients with type 1 diabetes (T1D). tirzepatide is a novel, once-weekly dual agonist for glucose-dependent insulin-stimulating polypeptide (GIP, aka gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor. tirzepatide is a single molecule that activates the body's GIP and GLP-1 receptors. Both GIP and GLP-1 are natural incretin hormones that promote insulin secretion. tirzepatide combines the effects of two insulin-promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.
In May 2022, tirzepatide was approved by the US FDA to supplement diet and exercise for improving blood sugar control in adults with type 2 diabetes (T2D). It is worth mentioning that tirzepatide is the first and only GIP/GLP-1 receptor agonist approved by the US FDA, and it also represents the first new class of hypoglycemic drugs approved for market in the past decade. tirzepatide is also under regulatory review in the European Union, Japan and several other markets.
Data showed that patients receiving tirzepatide 5mg achieved a 1.8% to 2.1% reduction in average blood sugar (A1C) levels; Patients treated with tirzepatide10mg and 15mg achieved a 1.7% to 2.4% reduction in average blood sugar (A1C) levels. In addition, in terms of weight loss, the key secondary endpoint of all studies, patients treated with tirzepatide have lost an average of 12 pounds (dose 5mg) to 25 pounds (dose 15mg).
In terms of safety, adverse events exceeding 5% in patients treated with tirzepatide include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and stomach (abdominal) pain.
